tickdelta
Sign in

Tickdelta is free for now. Sign up and get Pro free

← Screener

SOLVSolventum

Health care · Medical Instruments · NYSE
Compare with peers → Embed

The numbers SOLV said it expected, in its earnings releases of the last 3 years, next to what it then reported for the same period. Each target links to the sentence in the release; each result to the 10-Q or 10-K it was first reported in.

TargetWhat the company saidReportedResult
Free cash flow (company-defined)
Fiscal 2026
Given $200.00M to $300.00M release 2026-08-05
Kept $200.00M to $300.00M release 2026-11-05
– No standard number
The company's words
Solventum is updating its full year 2026 guidance as follows: … Increased free cash flow to be in the range of $200 million to $300 million; from prior estimate of ~$200M release 2026-08-05
Solventum is updating its full year 2026 guidance as follows: … Affirming free cash flow in the range of $200 million to $300 million release 2026-11-05
Diluted EPS (company-defined)
Fiscal 2026
Given $6.40 to $6.60 release 2026-02-26
Kept $6.40 to $6.60 release 2026-05-05
Raised $7.10 to $7.20 release 2026-08-05
Raised $7.20 to $7.30 release 2026-11-05
– No standard number
The company's words
Solventum is providing its full year 2026 guidance as follows: … Adjusted EPS of $6.40 to $6.60 release 2026-02-26
Solventum is affirming its full year 2026 guidance: … Adjusted EPS estimated to be toward the high end of existing $6.40 to $6.60 guidance range release 2026-05-05
Solventum is updating its full year 2026 guidance as follows: … Increased adjusted EPS range to $7.10 to $7.20; from the upper end of prior range of $6.40 to $6.60 release 2026-08-05
Solventum is updating its full year 2026 guidance as follows: … Increased adjusted EPS range to $7.20 to $7.30; from prior range of $7.10 to $7.20 release 2026-11-05
Free cash flow (company-defined)
Fiscal 2025 (ended 2025-12-31)
Given $450.00M to $550.00M release 2025-02-27
Kept $450.00M to $550.00M release 2025-05-08
Kept $450.00M to $550.00M release 2025-08-07
– No standard number
The company's words
Solventum is providing its full-year 2025 guidance … Free cash flow of $450M to $550M release 2025-02-27
Solventum is updating its full year 2025 guidance to reflect underlying business performance and flexibility to navigate the dynamic macroeconomic environment as follows: … Free cash flow in the range of $450M to $550M; no change release 2025-05-08
Solventum is updating its full year 2025 guidance to reflect underlying business performance and flexibility to navigate the dynamic macroeconomic environment as follows: … Free cash flow in the range of $450M to $550M; no change release 2025-08-07
Diluted EPS (company-defined)
Fiscal 2025 (ended 2025-12-31)
Given $5.45 to $5.65 release 2025-02-27
Kept $5.45 to $5.65 release 2025-05-08
Raised $5.80 to $5.95 release 2025-08-07
Raised $5.98 to $6.08 release 2025-11-06
– No standard number
The company's words
Solventum is providing its full-year 2025 guidance … Adjusted EPS of $5.45 to $5.65 release 2025-02-27
Solventum is updating its full year 2025 guidance to reflect underlying business performance and flexibility to navigate the dynamic macroeconomic environment as follows: … Adjusted EPS in the range of $5.45 to $5.65; no change release 2025-05-08
Solventum is updating its full year 2025 guidance to reflect underlying business performance and flexibility to navigate the dynamic macroeconomic environment as follows: … Increased adjusted EPS range to $5.80 to $5.95; from prior range of $5.45 to $5.65 release 2025-08-07
Solventum is updating its full year 2025 guidance as follows: … Increased adjusted EPS range to $5.98 to $6.08; from prior range of $5.88 to $6.03 release 2025-11-06
Free cash flow (company-defined)
Fiscal 2024 (ended 2024-12-31)
Given $700.00M to $800.00M release 2024-05-09
Kept $700.00M to $800.00M release 2024-08-08
Raised $750.00M to $850.00M release 2024-11-07
– No standard number
The company's words
Solventum reaffirms its full-year 2024 guidance: … Free cash flow of $700M to $800M release 2024-05-09
Solventum is raising its full-year 2024 guidance … Free cash flow of $700M to $800M (no change to prior guidance) release 2024-08-08
Solventum is raising its full-year 2024 guidance … Free cash flow of $750M to $850M (previously $700M to $800M) release 2024-11-07
Diluted EPS (company-defined)
Fiscal 2024 (ended 2024-12-31)
Given $6.10 to $6.40 release 2024-05-09
Raised $6.30 to $6.50 release 2024-08-08
Raised $6.50 to $6.65 release 2024-11-07
– No standard number
The company's words
Solventum reaffirms its full-year 2024 guidance: … Adjusted EPS of $6.10 to $6.40 release 2024-05-09
Solventum is raising its full-year 2024 guidance … Adjusted EPS of $6.30 to $6.50 (previously $6.10 to $6.40) release 2024-08-08
Solventum is raising its full-year 2024 guidance … Adjusted EPS of $6.50 to $6.65 (previously $6.30 to $6.50) release 2024-11-07

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (11 releases since 2024-05-09), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Next Archive →

Work on SOLV in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/SOLV/export.csv") into a cell.